PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
about
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsDacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?The Evolution of Therapies in Non-Small Cell Lung CancerOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesCombating acquired resistance to tyrosine kinase inhibitors in lung cancerManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerIrreversible EGFR-TKIs: dreaming perfectionCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaResistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategiesProfile of neratinib and its potential in the treatment of breast cancerThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerDeveloping irreversible inhibitors of the protein kinase cysteinomeNovel mutant-selective EGFR kinase inhibitors against EGFR T790MStructural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptorStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsAcquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerThree generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerMechanisms of resistance to EGFR-targeted drugs: lung cancerNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidencePharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceErbB polymorphisms: insights and implications for response to targeted cancer therapeuticsALK and NSCLC: Targeted therapy with ALK inhibitorsEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentOptimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitorsMET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
P2860
Q24600031-6FA2EE00-E4FF-4A18-820A-39DF005BF055Q26744284-74608F91-3AE8-4A6B-A840-C799181F7BCAQ26745427-A4DCB113-0124-4E68-A2D8-8E4FF1F6BD32Q26750428-FCBF1EC4-BE23-4964-9930-690BC62DACE4Q26778318-5C1C65BA-2C27-4866-9C91-F908DE139221Q26786932-421590ED-C72D-4701-89AB-BD34AB2BB737Q26795556-BE284CDC-641F-4209-939A-F8AF00007766Q26797297-0EC46AE0-9599-46EB-B15B-EDAA67189913Q26824877-7DE74CBB-71CB-4B25-8E18-AE47CB08DA76Q26865779-9950AFC9-9049-4051-9B4C-BD643BA7E1BAQ26866186-9DAA0531-A779-43B9-8E73-D2695324513CQ26991953-54B594AE-691D-40C9-ABEE-D1E37E9464B7Q27004161-83241532-A993-441A-A009-614C389E8E9DQ27012540-FEC5FD34-FFAB-4682-970C-B45B83990092Q27021738-88BEC11F-E6EC-4913-BE26-0BB33F2D5964Q27027983-A74C21C2-27E3-4432-B710-38FEA4DD2D9CQ27658766-20021C3D-9796-4DD9-9E75-858B614A338EQ27677383-6A3C8E2C-EE13-442F-88D7-5B17AB618C0CQ27680966-F4D852D4-2B6E-41A3-AB52-72B4DDAAE314Q27851440-8EE9F2F1-7B36-403C-8653-F28817432931Q27851628-41B25F2D-754E-4DC7-83E7-5313D82DF84FQ27851710-46B54CD9-D0A9-4E86-A7EA-07B040CF2B26Q27851896-712FC05B-0686-466C-B340-75B7B14D2B57Q27853013-0435072D-0D8E-434C-A45A-E3D6BD0D77F2Q27853015-B8CB7F13-6097-48E6-98A4-65BD5AF04AA2Q27853122-6096BF97-971E-48B0-B1FB-47F5661FEFF3Q27853154-EFA71E0B-0CB0-47D6-946A-55997C6D978AQ27853162-CFC6DA57-5E47-4F66-BF91-79EDA7BE25B1Q27853236-5A8C22D3-F256-4319-8D65-F5EF581A0876Q28075704-79AE30BC-8142-4B14-BD4F-E95AC053B3FFQ28077415-8ED9BDCE-87EA-4525-9A2A-C38B5B2411FCQ28079320-6A364219-8743-4C8B-AFE5-6AD9E53A2A62Q28080730-32BEF172-5E53-4109-81B0-509EEA81D6FAQ28083239-29118BA8-1D2F-4100-92F3-89ED58B7CFADQ28084565-775E9774-A3CB-4341-8FB6-1C9DED45203CQ28393324-ED4CC0A0-0AFC-45AB-B462-E0A21D51257FQ28394310-932092DB-740F-46F4-B861-9AEC922506DEQ28533949-8145BA3D-C278-4725-8041-9A09AC7CF411Q28535038-C11859D1-0692-4029-8FFD-F4BA57CA413DQ30502341-9F266F76-F67F-4B40-ABCD-8B146A2AFEC0
P2860
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
PF00299804, an irreversible pa ...... at are resistant to gefitinib.
@en
type
label
PF00299804, an irreversible pa ...... at are resistant to gefitinib.
@en
prefLabel
PF00299804, an irreversible pa ...... at are resistant to gefitinib.
@en
P2093
P50
P1433
P1476
PF00299804, an irreversible pa ...... at are resistant to gefitinib.
@en
P2093
Andrea J Gonzales
Christopher-Michael Gale
Eugene Lifshits
Geoffrey I Shapiro
George N Naumov
Irene W Althaus
James E Bradner
James M Nelson
Jeffrey A Engelman
P304
11924-11932
P356
10.1158/0008-5472.CAN-07-1885
P407
P577
2007-12-01T00:00:00Z